Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma: further explanation of a dose-escalating pilot study conducted primarily to consider the safety of this pharmacological modification.
Curnow
A
A
Campbell
S M
SM
D002280:Basal Cell Carcinoma / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D010778:Photochemotherapy / Q000009:adverse effects / Q000379:methods*; D017319:Photosensitizing Agents / Q000008:administration & dosage*; D010865:Pilot Projects; D011728:Pyridones / Q000008:administration & dosage* / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy*
D007502:Iron Chelating Agents; D017319:Photosensitizing Agents; D011728:Pyridones; C068543:1,2-diethyl-3-hydroxypyridin-4-one